Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 8/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1383077 | 0.98 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPTNPC1RAB9ATP53 | |
| SCHEMBL7841197 | 0.95 | SMN1; SMN2 (0.47) | SMN1; SMN2MAPTNPC1RAB9ATP53 | |
| SCHEMBL8590406 | 0.93 | EPHX1 (0.54) | SMN1; SMN2MAPTNPC1RAB9ATP53 | |
| SCHEMBL8589909 | 0.92 | EPHX1 (0.56) | SMN1; SMN2MAPTNPC1RAB9ATP53 | |
| SCHEMBL7750794 | 0.85 | EPHX1 (0.46) | SMN1; SMN2MAPTNPC1RAB9ATP53 | |
| SCHEMBL7194159 | 0.84 | EPHX1 (0.59) | SMN1; SMN2EPHX1ACHEMAPK1NPSR1 | |
| SCHEMBL28783627 | 0.83 | GNAI3 (0.55) | SMN1; SMN2MAPTNPC1RAB9ATP53 | |
| SCHEMBL2885378 | 0.82 | LIPE (0.44) | SMN1; SMN2MAPTNPC1RAB9ATP53 | |
| SCHEMBL6381523 | 0.82 | SMN1; SMN2 (0.40) | SMN1; SMN2MAPTNPC1RAB9ATP53 | |
| SCHEMBL7009651 | 0.81 | EPHX1 (0.40) | SMN1; SMN2MAPTNPC1RAB9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101899058-B | Method for preparing thiazolopyrimidine compound, thiazolopyrimidine compound and application thereof | FOURTH MILITARY MEDICAL UNIV | 2012-05-23 | — | — | CN | claimed |
| US-11739070-B2 | C5A receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2023-08-29 | — | — | US | disclosed |
| CN-101899058-B | Method for preparing thiazolopyrimidine compound, thiazolopyrimidine compound and application thereof | FOURTH MILITARY MEDICAL UNIV | 2012-05-23 | — | — | CN | disclosed |
| US-20100204187-A1 | Purine Derivatives | PALAU PHARMA, S.A. (ES) | 2010-08-12 | — | — | US | disclosed |
| EP-2044077-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | Glaxo Group Limited (GB) | 2009-04-08 | — | — | EP | disclosed |
| EP-1989185-A1 | THERAPEUTIC COMPOUNDS | Helicon Therapeutics, Inc. (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2008009700-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007100851-A1 | THERAPEUTIC COMPOUNDS | HELICON THERAPEUTICS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| EP-1709049-A1 | BICYCLIC IMIDAZOLE COMPOUNDS, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2006-10-11 | — | — | EP | disclosed |
| EP-1565468-A1 | NOVEL XANTHIN DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-08-24 | — | — | EP | disclosed |
| WO-2005063750-A1 | BICYCLIC IMIDAZOLE COMPOUNDS, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | WO | disclosed |
| US-20040242888-A1 | Process for producing 1-alkoxycarbonyl nitrogenous saturated heterocyclic derivative | TORAY FINE CHEMICALS CO., LTD., A CORPORATION OF JAPAN (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1460061-A1 | PROCESS FOR PRODUCING 1-ALKOXYCARBONYL NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | Toray Fine Chemicals Co., Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
| WO-2004046148-A1 | NOVEL XANTHIN DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-06-03 | — | — | WO | disclosed |
| EP-1102762-A2 | 2-SUBSTITUTED-1-PIPERIDYL BENZIMIDAZOLE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER INC. (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000008013-A2 | 2-SUBSTITUTED-1-PIPERIDYL BENZIMIDAZOLE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 2000-02-17 | — | — | WO | disclosed |
| EP-0719264-B1 | IMIDAZOLONE AND OXAZOLONE DERIVATIVES AS DOPAMINE ANTAGONISTS | MERCK SHARP & DOHME (GB) | 1997-12-29 | — | — | EP | disclosed |
| US-5698573-A | Imidazolone and oxazolone derivatives as dopamine antagonists | MERCK, SHARP & DOHME, LTD. (GB) | 1997-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242888-A1 | Process for producing 1-alkoxycarbonyl nitrogenous saturated heterocyclic derivative | DAO, DDO, ODC1 | SMN1; SMN2 2086/4885MAPT 1829/4885NPC1 830/4885 |
| US-20100204187-A1 | Purine Derivatives | JAK3, JAK1, JAK2 | SMN1; SMN2 3941/4885MAPT 4689/4885NPC1 3856/4885 |
| US-11739070-B2 | C5A receptor modulators | C5AR1, C3AR1, C5AR2 | SMN1; SMN2 4661/4885MAPT 4529/4885NPC1 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.